DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback